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We describe a unique case of fulminant myocarditis in a patient with presumed SARS-CoV-2 reinfection.
Patient had initial infection 4 months backand had COVID-19 antibody at the time of presentation. En-
domyocardial biopsy showed lymphocytic myocarditis, that is usually seen in viral myocarditis. The molecu-
lar diagnostic testing of the endomyocardial biopsy for cardiotropic viruses was positive for Parvovirus and
negative for SARS-CoV-2. Authors highly suspect co-infection of SARS-CoV-2 and Parvovirus, that possibly
triggered the immune cascade resulting in fulminant myocarditis. Patient was hemodynamically unstable
with ventricular tachycardia and was supported on VA ECMO and Impella CP. There was impressive recov-
ery of left ventricular function within 48 hours, leading to decannulation of VA ECMO in 72 h. This unique
case was written by the survivor herself.
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Case presentation
We describe a case of a 25-year-old medical student with no significant past medical history except for vitiligo.
She had coronavirus disease-19 (COVID-19)-like symptoms 4 months back after close contact with COVID-19.
SARS-CoV-2 IgG antibody was positive 3 months prior to presentation. She presented to the emergency room
this time with fever, abdominal pain, fatigue and vomiting for 2 days. Upon presentation she was found to be
in ventricular tachycardia (Figure 1). Echocardiogram showed biventricular failure and left ventricular ejection
fraction (LVEF) of 5–10%. She was defibrillated externally to normal sinus rhythm, however, continued to be
hemodynamically unstable. Bilateral Impellas (Impella CP and Impella RP (Abiomed, MA, USA) were placed
emergently. Despite this patient continued to deteriorate hemodynamically. So emergent peripheral veno arterial
extracorporeal membrane oxygenator (VA-ECMO) was placed with removal of RP Impella. Impella CP was retained
for left ventricular venting.
SARS-CoV-2 PCR was persistently positive on days 1, 7 and 10 of hospitalization. SARS-CoV-2 IgG antibody
was checked due to history of COVID infection, which came back positive on day 1. Inflammatory markers
and troponin were elevated (Table 1). For further work up of fulminant myocarditis (FM) endomyocardial
biopsy was done. Biopsy showed lymphocytic infiltrates consistent with viral myocarditis (Figure 2). Small foci
of myocardial necrosis were seen as well. Immunohistochemistry was negative. The molecular diagnostic testing
of the endomyocardial biopsy for cardiotropic viruses was positive for Parvovirus-19. SARS-CoV 2 PCR was
negative. The cycle threshold (ct) value for Parvovirus was 27 ct (value less than 29 ct indicating high viral load).
The electron microscopy of the biopsy did not show any viral inclusion particles. Serum Parvovirus antibody
testing IgM was negative (0.42 Index value) and IgG was positive (7.7 Index Value). Rest of the viral panel was
negative. Autoimmune panel was positive for anti-Ro antibody (5.1 test value). Chest X-ray was clear indicating
no pulmonary involvement.
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Figure 1. Electrocardiogram showing ventricular tachycardia upon presentation.
Table 1. Showing laboratory parameters.
Laboratory test Patient value Normal reference range
Troponin 10.65 ng/ml 0.03 ng/ml
BNP 117 pg/ml 0–100 pg/ml
IL-6 16.5 pg/ml 0–6.3 pg/ml
Ferritin 935.1 ng/ml 10–106 ng/ml
CRP 3.0 mg/dl 1.0 mg/dl
Creatinine 1.05 mg/dl 0.60–1.20 mg/dl
ALT 34 Units/l 7–52 Units/l
Figure 2. Endomyocardial biopsy showing lymphocytic myocarditis.
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Figure 3. Cardiac MRI findings. (A) CMR showing abnormal increased
T2 signal (80 ms) in the lateral wall of the left ventricle indicating
myocardial edema. (B) Transmural delayed gadolinium enhancement of
basal and mid anterolateral, inferolateral segments. (C) Short-axis view
of the CMR showing transmural delayed gadolinium enhancement.
Management
After initial stabilization on mechanical support, intravenous methylprednisolone 1 gm was started on day 1. On
day 2, moderate pericardial effusion (Supplementary Video 1) was noted, and pericardial window was done. At this
time COVID test results came back positive along with positive antibody. Due to the severity of the hemodynamic
compromise, she was treated with Remdesivir and convalescent plasma. Echocardiogram done the very next
day (48 hours of presentation) showed impressive recovery of biventricular function with near normal LVEF
(Supplementary Video 2). After another 24 hours of hemodynamic stability, patient was successfully decannulated
from VA ECMO and was maintained on Impella support alone.
The next day transesophageal echocardiogram was done prior to the removal of the Impella. Severe mitral
regurgitation was noted due to the flail and torn A3 component of anterior mitral valve. Mitral valve repair was
immediately performed with 6 gortex neo-chords to A3 of anterior mitral valve and annuloplasty ring. Separation
from cardiopulmonary bypass was delayed due to biventricular failure, however there was impressive recovery of
LVEF to normal once again in the operating room. Patient was extubated the next day.
Cardiac MRI (CMR) done prior to discharge showed transmural late gadolinium enhancement of basal-mid
anterolateral and inferolateral segments (Figure 3). Patient was continued on high dose steroids and was discharged
to home in stable condition and normal LVEF (Supplementary Video 3) on day 13.
At the 4-month follow-up, the patient continues to do well on medical therapy with preservation of LVEF.
Currently, she is on a slow steroid wean.
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Discussion
This case is unique for various reasons. SARS-CoV-2 PCR was positive after 4 months of initial infection, raising the
possibility of reinfection. According to CDC patients can get reinfection after 3 months of initial infection. However,
the patient also had Positive SARS-CoV-2 IgG antibody at the time of presentation. SARS-CoV-2 IgG antibody is
thought be highly protective in preventing reinfection. Ours is the first case to isolate Parvovirus genome in the
myocardial tissue in a patient with COVID-19. FM as the initial presentation of SARS-CoV-2 infection, requiring
ECMO for hemodynamic support is rare. The other distinctive features include rapid recovery of FM within
48 hours of presentation and ECMO decannulation in 72 hours. This case report is quite unique as one the
authors of the case report is the survivor herself.
Cardiovascular involvement from SARS-CoV-2 although is widely reported, in general is uncommon. FM in
COVID patients has been limited to case reports [1]. The exact mechanism of myocarditis in COVID patients is
not clear. SARS-CoV-2 is not thought to be a cardiotropic virus [2]. Isolation of the virus from the cardiomyocyte in
the autopsy or biopsy specimen has not been possible [2]. However viral particles have been found in cardiomyocyte
in one pediatric patient [3] and in the myocardial macrophage in another case [4]. Alternatively, virus can trigger
inflammatory response in the form of SIRS, lymphopenia, macrophage activation and cytokine storm releasing
IL-6, IL-10 and TNF-α which can cause myocarditis [5].
Co-infection with another virus or bacteria is a known common phenomenon resulting in myocarditis. Ours
is the first case to demonstrate parvovirus in the endomyocardial biopsy in a patient otherwise with presumed
COVID myocarditis. Parvovirus is a cardiotropic virus and FM has been described [6]. Shah et al. noticed high
coinfection rate (22.4%) in COVID-19 patients [7]. Probably we can postulate that infection with SARS-CoV-2
and Parvovirus co-infection triggered immune cascade and lead to FM. In this patient IgM for parvo virus was
negative and IgG was positive indicating past infection. IgG antibody production usually occurs 18–24 days after
the infection and can persist for years.
It is not very clear if the patient contracted reinfection as she was persistently positive for PCR in the presence
of SARS-CoV-2 antibody. However, it is currently not known if or how antibody testing results correlate with
immunity to SARS-CoV-2 infection. COVID reinfection is being reported as early as 4 weeks from initial infection
and the second infection can be more severe [8,9]. Alternatively, patients can persistently test positive despite clearing
the infection, partly due to presence of viral particles.
There is a prevalent theory of a link between acute myocarditis (AM) and autoimmune disease; the association
is seen in about 7.2% of AM patients [10]. The patient was positive for anti-Ro antibodies, had significant
inflammation on CMR and had history of vitiligo which can be associated other autoimmune conditions. These
factors were taken into consideration in initiating glucocorticoid therapy. Since her LVEF recovered rapidly,
concomitant therapy with azathioprine, cyclosporine and Mycophenolate mofetil were not considered due to
lack of convincing evidence from a risk versus benefit analysis. Notably, the patient received convalescent plasma
immunoglobulin during her stay. Research regarding Immunoglobin as AM treatment is well described in children.
The Immunoglobulin therapy may have a role in AM as cardiac autoantibodies are frequently seen in myocarditis.
One may consider using Immunoglobulin therapy especially in hemodynamically unstable patient as a treatment
modality [11].
Conclusion
FM with cardiogenic shock can be expected in COVID patients and requires a full extent of hemodynamic support
along with anti-viral treatment. This case raises the impact of possible co-infection in COVID patients. This case
also highlights the diagnostic challenges that we face in the era of pandemic.
Summary points
• Cardiovascular complications although are uncommon in SARS-CoV-2 infection, is increasingly being reported.
• Fulminant Myocarditis can be seen in patients with SARS-CoV-2 infection.
• Full hemodynamic support when appropriate should be considered, as there is chance of recovery of left
ventricular function.
• Co-infection should be in the differential when treating patients with SARS-CoV-2 infection.
10.2217/fca-2020-0237 Future Cardiol. (Epub ahead of print) future science group
Fulminant myocarditis: COVID or not COVID? Reinfection or co-infection? Case Report
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/sup
pl/10.2217/fca-2020-0237
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or finan-
cial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria,
stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Informed consent disclosure
The authors state that they have obtained verbal and written informed consent from the patient/patients for the inclusion of their
medical and treatment history within this case report.
References
Papers of special note have been highlighted as: • of interest
1. Bernal-Torres W, Herrera-Escandón Á, Hurtado-Rivera M, Plata-Mosquera CA. COVID-19 fulminant myocarditis: a case report. Eur
Heart J Case Rep. 4(FI1), 1–6 (2020).
2. Ozieranski K, Tyminska A, Jonik S et al. Clinically suspected myocarditis in the course of severe acute respiratory syndrome novel
coronavirus-2 infection: fact or fiction? Eur. J. Card. Fail. 27(1), 92–96 (2020).
• Describes the various COVID myocarditis cases in the literature.
3. Dolhnikoff M, Ferranti JF, de Almeida M RA et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem
inflammatory syndrome. Lancet Child. Adolesc. Health. 4(10), 790–794 (2020).
• First paper to report SARS-Co-V-2 viral particle inside the cardiac myocyte.
4. Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A. Myocardial localization of coronavirus in COVID-19 cardiogenic
shock. Eur. J. Heart Fail. 22, 911–915 (2020).
• Paper reporting SARS-CoV-2 viral particle in the macrophage in the endomyocardial biopsy.
5. Siripanthong B, Nazarian S, Muser D et al. Recognizing COVID-19–related myocarditis: the possible pathophysiology and proposed
guideline for diagnosis and management. Heart Rhythm. 17(9), 1463–1471 (2020).
• Describes the possible mechanisms of COVID-19 related myocarditis.
6. Spartalis M, Tzatzaki E, Spartalis E, Damaskos C, Mavrogeni S, Voudris V. Parvovirus B19 Myocarditis of Fulminant Evolution.
Cardiol. Res. 8(4), 172–175 (2017).
7. Shah N. Higher co-infection rates in COVID19. https://medium.com/@nigam/higher-co-infection-rates-in-covid19-b24965088333
(2020).
8. Tillett RL, Sevinsky JR, Hartley PD et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect. Dis.
S1473-3099(20), 30764–30767 (2020).
9. Prado-Vivar B, Becerra-Wong M, Guadalupe JJ et al. COVID-19 re-infection by a phylogenetically distinct SARS-CoV-2 variant, first
confirmed event in South America. SSRN. https://doi.org/10.2139/ssrn.3686174 (2020).
10. Ammirati E, Cipriani M, Frigerio M et al. Clinical presentation and outcome in a contemporary cohort of patients with acute
myocarditis. Circulation 138(10), 1088–1099 (2020).
11. Hendren N, Drazner M, Bozkurt B, Cooper L. Description and proposed management of the acute COVID-19 cardiovascular
syndrome. Circulation 141, 1903–14 (2020).
• Describes the various treatment options for cardiac injury in COVID-19.
future science group 10.2217/fca-2020-0237
